A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses responsible for the world's most common serious liver infections and ...

While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Hepatitis B virus infection remains one of the leading causes of liver ... In a review (DOI: 10.1016/j.gendis.2024.101215) published in Genes & Diseases on February 3, 2024, a team of researchers from ...

The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Hepatitis B can lead to liver disease. But we can prevent and manage this viral infection. Here’s what we know about the ...